DERMA SCIENCES langfristiges Topinvest!

Aktien Ausstehend ca 10,6 Millionen
noch auszugeben ca 4,6 Millionen
Bei den fast wöchentlich zu berichteten Owners, gehe ich davon aus, das mitlerweile alles an den Mann gebracht wurde?
www.ir.dermasciences.com/profiles/investor/...ngID=1&s=302
Bei einem Kurs von 10 Dollar, hätte Derma Sciences eine MK von 150 Millionen Dollar.

DSC 127 ist für jede Indication mindesten 1 Milliarde Wert?
Dieses Jahr soll die Phase 3 in Diabetic Foot Ulcers gestartet werden.

Desweiteren wird geprüft ob Studien in Narbenreduktion, Verbrennungen und Chronische Wunden gestartet werden.

Die Präsentation von der LHA Life Sciences & Medical Technologies Virtual Conference
ist wirklich sehr lesenswert(vor allem Slid 14 Potential U.S. Sales Ramp Up)
www.ir.dermasciences.com/profiles/investor/EmailCheck.asp

Also bei Zulassung in nur einer Indication minimum 100 Dollar pro Share....

Ich rechne hier aber mit einer Übernahme für lau...

Wollen wir mal hoffen das die Übernahme nicht kommt und bald ein Partner mit ner fetten Upfrontzahlung präsentirt wird?

Gruss

www.ir.dermasciences.com/Profiles/Investor/...I&Validate=4

www.linkedin.com/in/paulgilbert1992

Bekommt er demnächst auch einen Posten bei DSCI?

in den Verwaltungsrat vorgeschlagen.

b2i.api.edgar-online.com/EFX_dll/...Fv_4rwenE-9&ID=8490759

und sich positioniert.

Wann treiben sie den Preis hoch, und bereiten die Firma für den Verkauf vor????

Derma Sciences Reports Record Fourth Quarter Net Sales; Sales Force Expansion Ahead of Schedule; Continues Progress toward Phase 3 Trials

Conference call begins at 11:00 a.m. Eastern time today

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the three and 12 months ended December 31, 2011. Highlights of the fourth quarter of 2011 and recent weeks include:

   Net sales were $16.5 million, up 8% over the prior-year fourth quarter, while net sales for the year were $62.6 million, up 11% over 2010
   Advanced wound care product sales were $4.5 million for the fourth quarter of 2011, up 23% and were $15.9 million for the year, up 37% over the prior year
   Advanced wound care products accounted for 27% of net sales, up from 24% in the prior-year quarter
   Traditional wound care product sales for the quarter were $12.1 million, up 4% from $11.7 million in the prior year quarter
   Hired 10 advanced wound care sales representatives during the first quarter of 2012 for a total of 36 as of March 26th, well ahead of schedule
   Positive meeting with the U.S. Food and Drug Administration (FDA) regarding preparations to begin Phase 3 trials with DSC127 for the treatment of diabetic foot ulcers
   Fourth quarter 2011 net loss was $2.5 million, or $0.23 per share compared with $0.3 million, or $0.05 per share, in the prior year quarter as planned investments in sales force expansion and research and development added to expenses

Derma Sciences to Acquire MedEfficiency; Expands Proprietary Advanced Wound Care Product Offering with High-Growth, Market-Leading, Gold-Standard Treatment for Diabetic Foot Ulcers
www.ir.dermasciences.com/profiles/investor/...amp;Category=440

kauft noch mal 100.000 Stück für 9.25
finance.yahoo.com/q/it?s=DSCI+Insider+Transactions

amp2012.com/

Derma Sciences Announces Pricing of Underwritten Registered Direct Offering of Common Stock

Derma Sciences, Inc. (the "Company") (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced the pricing of an underwritten registered direct offering of 2,125,000 shares of common stock at a price of $9.25 per share. The offering is expected to close on or about April 5, 2012. Piper Jaffray & Co. is acting as the sole underwriter of the offering.

Net proceeds from the sale of the shares of common stock, after underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $17.9 million. The Company plans to use the net proceeds from the offering for the continued development of DSC127 and for general corporate purposes.

When available, copies of the prospectus supplement and accompanying prospectus relating to the offering may be obtained from the Securities and Exchange Commission at www.sec.gov, or from Piper Jaffray & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or email prospectus@pjc.com, or by telephone at (800) 747-3924.

This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This offering may be made only by means of a prospectus supplement and accompanying base prospectus.
www.ir.dermasciences.com/profiles/investor/...amp;Category=440

finance.yahoo.com/news/...es-hold-first-quarter-152200173.html

http://www.ariva.de/depot/private/positions.m?depot_id=417284

biz.yahoo.com/e/120605/dsci8-k.html

letztes billiges einsteigen ist angesagt...

Derma Sciences acquires long-term exclusive rights to NIMBUS technology
finance.yahoo.com/news/...es-acquires-long-term-113143297.html

Derma Sciences Reports Second Quarter 2012 Financial Results

-Advanced Wound Care Products up 52%; Represents 33% of Net Sales-

-DSC127 Drug Program on Track for Phase 3 Start by Year End-

Conference call begins at 11:00 a.m. Eastern time today
finance.yahoo.com/news/...eports-second-quarter-113000077.html

gehts bald rund Chartmäßig

Derma Sciences Launches MEDIHONEY® HCS in the U.S.

Novel Combination of MEDIHONEY® and XTRASORB® Hydrates Dry Wounds and Absorbs Fluid from Wounds that are Draining
finance.yahoo.com/news/...aunches-medihoney-hcs-113000429.html

Derma Sciences on Track to Begin Phase 3 Program with DSC127 in December Following Meeting with FDA
finance.yahoo.com/news/...ces-track-begin-phase-113000927.html

das es von Bekanntgabe der Phase 2 Ergebnisse bis Start Phase 3, (wenns denn mal so kommen sollte) fast 2 Jahre ins Land gezogen sind. Verdammt lange finde ich.

Derma Sciences Reports Third Quarter 2012 Financial Results

-Net Sales up 24%, Advanced Wound Care Sales up 67%, Traditional Wound Care Sales up 9%-

-DSC127 Drug Program on Track for Phase 3 Start by Year End-

Conference call begins at 11:00 a.m. Eastern time today
finance.yahoo.com/news/...reports-third-quarter-123000442.html

nach KE..die Verkäufer kommen wieder billiger an Ihre Teile.

finance.yahoo.com/news/...s-commencement-public-210400175.html